We can’t show the full text here under this license. Use the link below to read it at the source.
Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial
Tirzepatide’s link to lowering blood pressure in different groups from the SURMOUNT-1 trial
AI simplified
Abstract
Tirzepatide treatment led to a significant net reduction of 6.8 mm Hg systolic and 4.2 mm Hg diastolic blood pressure after 72 weeks in participants with obesity or overweight.
- Blood pressure showed a rapid decline during the first 24 weeks of tirzepatide treatment, followed by stabilization.
- Participants receiving tirzepatide were more likely to achieve normal blood pressure at week 72 compared to those on placebo (58.0% vs 35.2%).
- The reduction in blood pressure was consistent across various baseline blood pressure subgroups.
- Weight loss accounted for 68% of the reduction in systolic and 71% in .
- While low blood pressure adverse events were infrequent, they occurred more often in the tirzepatide group.
AI simplified
Key numbers
6.8 mm Hg
Reduction
Net change from baseline to week 72 for tirzepatide vs. placebo
4.2 mm Hg
Reduction
Net change from baseline to week 72 for tirzepatide vs. placebo
58.0%
Participants Achieving Normal Blood Pressure
Proportion of participants at week 72 for tirzepatide vs. placebo